- Home
- CHNR vs ALZN Comparison
CHNR vs ALZN Comparison
Compare CHNR & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHNR | ALZN |
|---|---|---|
| Founded | N/A | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 4.6M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CHNR | ALZN |
|---|---|---|
| Price | $4.08 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 10.7K | ★ 42.4K |
| Earning Date | 05-15-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 76.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.18 | $0.84 |
| 52 Week High | $8.20 | $2.68 |
Technical Indicators
Market Signals| Indicator | CHNR | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 56.90 | 62.43 |
| Support Level | $3.93 | $1.04 |
| Resistance Level | $4.25 | $2.22 |
| Average True Range (ATR) | 0.18 | 0.08 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 72.21 | 95.24 |
Price Performance
Historical ComparisonAbout CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.